| Name | Title | Contact Details |
|---|
Champions Oncology is a company that develops technology solutions and services for personalizing the development and use of oncology drugs. Their technology-enabled research platforms empower biopharma to create a comprehensive understanding of tumor ...
VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.
AcariaHealth is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company`s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process.